Nelson, Van Denburg & Campbell Wealth Management Group, LLC Apellis Pharmaceuticals, Inc. Transaction History

Nelson, Van Denburg & Campbell Wealth Management Group, LLC

$2.53 Billion
Q1 2025

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 17, 2025	BUY	$26.18 - $35.42 $5,759 - $7,792	220 New	220 $7,000
Q1 2024 Apr 30, 2024	BUY	$55.39 - $72.47 $22,211 - $29,060	401 New	401 $23,000
Q3 2023 Oct 17, 2023	BUY	$23.65 - $89.22 $24,572 - $92,699	1,039 Added 37.55%	3,806 $144,000
Q2 2023 Jul 19, 2023	SELL	$76.68 - $93.31 $78,827 - $95,922	-1,028 Reduced 27.09%	2,767 $252,000
Q1 2023 May 10, 2023	BUY	$46.59 - $66.96 $19,241 - $27,654	413 Added 12.21%	3,795 $250,000
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $146,237 - $206,437	3,382 New	3,382 $174,000

Others Institutions Holding APLS

# of Institutions

300

Shares Held

111M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $1.91B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nelson, Van Denburg & Campbell Wealth Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nelson, Van Denburg & Campbell Wealth Management Group, LLC with notifications on news.

Account